Source link : https://www.newshealth.biz/health-news/tavapadon-marches-on-in-parkinsons-disease/
PHILADELPHIA — Tavapadon, an experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson’s disease (PD), was shown to significantly reduce disease burden in two phase 3 trials TEMPO trials. In the TEMPO-3 trial, topline findings reported earlier this year showed patients with PD and motor fluctuations receiving once-daily tavapadon as adjunct therapy to […]
Author : News Health
Publish date : 2024-10-08 14:16:11
Copyright for syndicated content belongs to the linked Source.
Categories